Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 21 | 12 | −9 |
| SharesConverted for a 1-for-15 split | 137.5K | 143.5K | +6.07K (+4.4%) |
| Value | $878.3K | $419.1K | −$459.2K (−52.3%) |
New holders (2)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 25,597 | $74.5K | 0.00% |
| Tower Research Capital LLC (TRC) | 51 | $152 | 0.00% |
Sold out (11)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Raymond James & Associates | 138,040 | $58.9K |
| Citadel Advisors LLC | 40,844 | $17.4K |
| Virtu Financial LLC | 31,633 | $13.0K |
| Western Wealth Management, LLC | 29,537 | $12.6K |
| Cambridge Investment Research Advisors, Inc. | 28,500 | $12.0K |
| Raymond James Financial Services Advisors, Inc. | 27,900 | $11.9K |
| Geode Capital Management, LLC | 27,177 | $11.6K |
| Belpointe Asset Management LLC | 14,050 | $5.99K |
| BNP Paribas Arbitrage, SA | 13,716 | $5.85K |
| Jane Street Group, LLC | 13,189 | $5.63K |
| Northwestern Mutual Wealth Management Co | 10 | $4 |